Literature DB >> 15468603

Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.

Taff Jones1.   

Abstract

Acambis, in collaboration with Aventis Pasteur, is developing a chimeric vaccine based on a recombinant yellow fever vaccine for the potential prevention of dengue virus infection. The vaccine is undergoing phase I clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15468603

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  2 in total

1.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

2.  Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.

Authors:  Charles E McGee; Konstantin Tsetsarkin; Dana L Vanlandingham; Kate L McElroy; Jean Lang; Bruno Guy; Thierry Decelle; Stephen Higgs
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.